Artiva Biotherapeutics, Inc. (ARTV)
Nasdaq: ARTV · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2020
Who owns Artiva Biotherapeutics, Inc.
As filed with the SECHolders of 5% or more
3
RA Capital Management, L.P. holds 37.9% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Jul 23, 2026 says.
Directors and officers
20
report now, of 23 people on the record since 2024. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Jul 23, 2026 · Common Stock, par value $0.0001 per share · 36.6% in Jun 15, 2026
GC Corp
SCHEDULE 13D/A · filed May 28, 2026 · Common Stock
Viking Global Investors LP
SCHEDULE 13G · filed May 18, 2026 · Common Stock, $0.0001 par value per share
venBio Global Strategic Fund III, L.P.
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Andrew J. Schwab
SCHEDULE 13G/A · filed Aug 10, 2026 · Common stock, par value $0.0001 · reported falling below 5%
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 16, 2025 · Common Stock · reported falling below 5%, from 5.1% in Apr 23, 2025
What ARTV reports owning in othersstakes of 5% or more, and other ties
Artiva Biotherapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
23sales
20purchases
6sales on a scheduled plan
5people selling
$2.9Msold, in dollars
$92.7Mbought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 37 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Aslan Fred | Chief Executive Officer | 8 | $2.1M | 4 | 0 | $0 |
| Bush Jennifer | COO, CLO, Compliance Officer | 4 | $300,000 | 0 | 0 | $0 |
| Horan Christopher | Chief Tech Operations Officer | 4 | $300,000 | 0 | 0 | $0 |
| Banerjee Subhashis | Chief Medical Officer | 6 | $200,000 | 2 | 0 | $0 |
| Kolchinsky Peter | director | 0 | $0 | 0 | 6 | $7.2M |
| Ra Capital Healthcare Fund LP | director | 0 | $0 | 0 | 4 | $1.9M |
| Ra Capital Nexus Fund, L.P. | director | 0 | $0 | 0 | 4 | $7.7M |
| Ra Capital Management, L.P. | director | 0 | $0 | 0 | 2 | $300,000 |
| Ra Capital Nexus Fund III, L.P. | director | 0 | $0 | 0 | 2 | $75.4M |
| Shah Rajeev M. | director | 0 | $0 | 0 | 2 | $200,000 |
| Gc Corp. | 10% owner | 0 | $0 | 0 | 2 | $16.5M |
| Raymon Heather | SVP, Research and Development | 1 | $0 | 0 | 0 | $0 |